213 related articles for article (PubMed ID: 23870042)
1. Persistence with first line anticholinergic medication in treatment-naïve overactive bladder patients.
Krhut J; Gärtner M; Petzel M; Sykora R; Nemec D; Tvrdik J; Skoupa J
Scand J Urol; 2014 Feb; 48(1):79-83. PubMed ID: 23870042
[TBL] [Abstract][Full Text] [Related]
2. Adherence, persistence and switch rates for anticholinergic drugs used for overactive bladder in women: data from the Norwegian Prescription Database.
Mauseth SA; Skurtveit S; Spigset O
Acta Obstet Gynecol Scand; 2013 Oct; 92(10):1208-15. PubMed ID: 23763552
[TBL] [Abstract][Full Text] [Related]
3. Comparing anticholinergic persistence and adherence profiles in overactive bladder patients based on gender, obesity, and major anticholinergic agents.
Lua LL; Pathak P; Dandolu V
Neurourol Urodyn; 2017 Nov; 36(8):2123-2131. PubMed ID: 28467609
[TBL] [Abstract][Full Text] [Related]
4. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience.
Wagg A; Compion G; Fahey A; Siddiqui E
BJU Int; 2012 Dec; 110(11):1767-74. PubMed ID: 22409769
[TBL] [Abstract][Full Text] [Related]
5. Treatments for overactive bladder: focus on pharmacotherapy.
Geoffrion R;
J Obstet Gynaecol Can; 2012 Nov; 34(11):1092-1101. PubMed ID: 23231848
[TBL] [Abstract][Full Text] [Related]
6. Long-term patterns of use and treatment failure with anticholinergic agents for overactive bladder.
Chancellor MB; Migliaccio-Walle K; Bramley TJ; Chaudhari SL; Corbell C; Globe D
Clin Ther; 2013 Nov; 35(11):1744-51. PubMed ID: 24091072
[TBL] [Abstract][Full Text] [Related]
7. Limitations of anticholinergic cycling in patients with overactive bladder (OAB) with urinary incontinence (UI): results from the CONsequences of Treatment Refractory Overactive bLadder (CONTROL) study.
Chancellor MB; Yehoshua A; Waweru C; Globe D; Cheng IN; Campbell KL; Joshi M; Pulicharam R
Int Urol Nephrol; 2016 Jul; 48(7):1029-36. PubMed ID: 27032397
[TBL] [Abstract][Full Text] [Related]
8. Anticholinergic therapy: do the patients take the pills prescribed?
Jundt K; Schreyer K; Friese K; Peschers U
Arch Gynecol Obstet; 2011 Sep; 284(3):663-6. PubMed ID: 21046135
[TBL] [Abstract][Full Text] [Related]
9. Increased risk of dementia among patients with overactive bladder treated with an anticholinergic medication compared to a beta-3 agonist: a population-based cohort study.
Welk B; McArthur E
BJU Int; 2020 Jul; 126(1):183-190. PubMed ID: 32167223
[TBL] [Abstract][Full Text] [Related]
10. Interventions do not enhance medication persistence and compliance in patients with overactive bladder: a 24 weeks, randomised, open-label, multi-center trial.
Sung HH; Han DH; Kim TH; Lee YS; Lee HN; Seo JT; Choo MS; Lee KS
Int J Clin Pract; 2015 Nov; 69(11):1309-15. PubMed ID: 26215431
[TBL] [Abstract][Full Text] [Related]
11. Effect of anticholinergic use for the treatment of overactive bladder on cognitive function in postmenopausal women.
Geller EJ; Crane AK; Wells EC; Robinson BL; Jannelli ML; Khandelwal CM; Connolly A; Parnell BA; Matthews CA; Dumond JB; Busby-Whitehead J
Clin Drug Investig; 2012 Oct; 32(10):697-705. PubMed ID: 22873491
[TBL] [Abstract][Full Text] [Related]
12. [Impact on cognitive function of anticholinergic drugs used for the treatment of overactive bladder in the elderly].
Kerdraon J; Robain G; Jeandel C; Mongiat Artus P; Gamé X; Fatton B; Scheiber-Nogueira MC; Vetel JM; Mares P; Petit AC; Amarenco G;
Prog Urol; 2014 Sep; 24(11):672-81. PubMed ID: 25214448
[TBL] [Abstract][Full Text] [Related]
13. Persistence and concomitant medication in patients with overactive bladder treated with antimuscarinic agents in primary care. An observational baseline study.
Sicras-Mainar A; Navarro-Artieda R; Ruiz-Torrejón A; Sáez-Zafra M; Coll-de Tuero G
Actas Urol Esp; 2016 Mar; 40(2):96-101. PubMed ID: 26556482
[TBL] [Abstract][Full Text] [Related]
14. Health Resource Utilization and Cost for Patients with Incontinent Overactive Bladder Treated with Anticholinergics.
Yehoshua A; Chancellor M; Vasavada S; Malone DC; Armstrong EP; Joshi M; Campbell K; Pulicharam R
J Manag Care Spec Pharm; 2016 Apr; 22(4):406-13. PubMed ID: 27023694
[TBL] [Abstract][Full Text] [Related]
15. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.
Cardozo L; Thorpe A; Warner J; Sidhu M
BJU Int; 2010 Aug; 106(4):506-14. PubMed ID: 20132203
[TBL] [Abstract][Full Text] [Related]
16. Anticholinergic medication use for female overactive bladder in the ambulatory setting in the United States.
Ju R; Garrett J; Wu JM
Int Urogynecol J; 2014 Apr; 25(4):479-84. PubMed ID: 24158462
[TBL] [Abstract][Full Text] [Related]
17. Antimuscarinic persistence patterns in newly treated patients with overactive bladder: a retrospective comparative analysis.
Sicras-Mainar A; Rejas J; Navarro-Artieda R; Aguado-Jodar A; Ruiz-Torrejón A; Ibáñez-Nolla J; Kvasz M
Int Urogynecol J; 2014 Apr; 25(4):485-92. PubMed ID: 24196653
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
[TBL] [Abstract][Full Text] [Related]
19. Persistence and Adherence of Anticholinergics and Beta-3 Agonist for the Treatment of Overactive Bladder: Systematic Review and Meta-Analysis, and Network Meta-Analysis.
Song YS; Lee HY; Park JJ; Kim JH
J Urol; 2021 Jun; 205(6):1595-1604. PubMed ID: 33207141
[TBL] [Abstract][Full Text] [Related]
20. Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature.
Sexton CC; Notte SM; Maroulis C; Dmochowski RR; Cardozo L; Subramanian D; Coyne KS
Int J Clin Pract; 2011 May; 65(5):567-85. PubMed ID: 21489081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
